For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 645,470 | 321,798.5* | 930,894 | 449,679 |
| General and administrative | 1,610,457 | 1,681,059.5* | 2,192,879 | 1,264,523 |
| Total operating expenses | 2,255,927 | 2,002,858 | 3,123,773 | 1,714,202 |
| Loss from operations | -2,255,927 | -2,002,858* | -3,123,773 | -1,714,202 |
| Interest income | 40,876 | 54,826.5* | 68,142 | 16,793 |
| Interest expense | 3,727 | -83,093.5* | 7,039 | 572,310 |
| Foreign currency exchange net | -5,090 | -3,840.5* | -3,919 | -2,316 |
| Total other income (expense), net | 32,059 | 134,079.5* | 57,184 | -557,833 |
| Loss before income taxes | -2,223,868 | -1,868,778.5* | - | - |
| Income tax benefit | -22,625 | -34,227.5* | - | - |
| Net loss | -2,201,243 | -1,834,551 | -3,066,589 | -2,272,035 |
| Basic EPS | -0.51 | -0.85 | -1.96 | -3.1 |
| Diluted EPS | -0.51 | -0.85 | -1.96 | -3.1 |
| Basic Average Shares | 4,300,980 | 2,157,076* | 1,560,909 | 731,817 |
| Diluted Average Shares | 4,300,980 | 2,157,076* | 1,560,909 | 731,817 |
ORAGENICS INC (OGEN)
ORAGENICS INC (OGEN)